CompaniesAjax Therapeutics
Ajax Therapeutics logo

Ajax Therapeutics

active
Cambridge, MA, United States
Founded 2019
Website
About

Computational chemistry and structural biology

Areas of Focus

Categories

Small Molecule PharmaceuticalBoston & New England
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

76

By Phase

PHASE1: 1

By Status

RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
Today
NCT06343805
Hover over trial bars to see details

Recent Trials

NCT06343805Lead Sponsor
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
PHASE1Recruiting
76 participants
Started: Oct 23, 2024 · Completed: Feb 15, 2027
Funding History (3)
D
May 13, 2024
Filing
D
Jun 1, 2021
Filing
D
Jun 28, 2019
Filing
Locations (1)
Headquarters
Cambridge, MA, United States
Map

Loading map...